

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code : 2666)

UNAUDITED OPERATION SUMMARY OF THE GROUP FOR THE THIRD QUARTER OF 2022

This announcement sets out the unaudited operation summary of Genertec Universal Medical Group Company Limited (the “**Company**”), together with its subsidiaries (the “**Group**”), for the third quarter ended 30 September 2022.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

During the third quarter of 2022, under the epidemic prevention and economic development in China, the Group continued to strategically plan, better accommodate the needs for pandemic control and made great efforts to promote business development; and the member medical institutions of the Group ensured daily operations and adhered to its own discipline, operation and service capacity building while undertaking important local epidemic prevention responsibilities. For the nine months ended 30 September 2022, the Group remained stable in operating results: the revenue of the Group increased by approximately 15.3% as compared with the corresponding period of 2021, the profit for the period increased by approximately 0.8% as compared with the corresponding period of 2021, and the profit for the period attributable to ordinary shareholders of the parent increased by approximately 0.5% as compared with the corresponding period of 2021, among which:

In respect of finance business, the Group continued to make progress while ensuring stability in the third quarter of 2022. With risk control as a top priority, the Company was committed to ensuring quality project development for customers. By keeping abreast of the market changes, the Company strived to control financing costs with a flexible approach to meet investment capital requirements. As at 30 September 2022, as compared with the first half of 2022, though interest-earning assets decreased

slightly (mainly due to the issuance of assets-backed securities), net interest margin and net interest spread both decreased slightly, asset quality always remained at a good level.

In respect of hospital group business, the overall operation of the member medical institutions managed by the Group was stable in the third quarter of 2022: affected by the spread of the epidemic in many places, nucleic acid testing increased greatly, resulting in a significant increase in the total number of visits, which increased by approximately 9% after excluding the nucleic acid visits as compared with the corresponding period of 2021; the number of medical examinations was affected by the epidemic, which was basically unchanged; the number of inpatients increased by approximately 10% as compared with the corresponding period of 2021; total medical business income grew by approximately 13% as compared with the corresponding period of 2021. In addition, relying on the hospital group, we continue to promote the business layout in several fields such as discipline operation and life cycle management of medical equipment. While serving the internal hospital group, we further hone the advantages of replicability and expand the market scale outside the health industry group.

In respect of financing support, the Group actively developed and took advantage of various financing instruments while ensuring its capital liquidity and prudent debt maturity structure, moderately controlled the foreign currency financing, and objectively managed the foreign exchange risk. The average funding cost for the first three quarters of this year remained stable as compared to that of 2021.

In addition, references are made to the Company's announcements dated 5 March 2020, 19 May 2020, 8 April 2021, 16 September 2021, 20 December 2021, 30 May 2022, 6 July 2022 and 5 September 2022 in relation to the issuance of the medium-term notes with an aggregate principal amount of RMB4.00 billion in the inter-bank market in the People's Republic of China (the "PRC") by China Universal Leasing Co., Ltd. (中國環球租賃有限公司) ("**Universal Leasing**"), a wholly-owned subsidiary of the Company. In accordance with the relevant laws and regulations of the PRC, the unaudited consolidated financial information of Universal Leasing for the nine months ended 30 September 2022 (the "**Universal Leasing Consolidated Financial Information**") has been published on the websites of Shanghai Clearing House (www.shclearing.com) and China Foreign Exchange Trade System (www.chinamoney.com.cn) on 28 October 2022. The Company's board of directors would like to draw the attention of its shareholders and investors to the following principal financial data of Universal Leasing:

PRINCIPAL CONSOLIDATED FINANCIAL DATA OF UNIVERSAL LEASING

*Unit: Thousand Yuan
Currency: RMB*

	As at 30 September 2022 (unaudited)	As at 31 December 2021 (audited)
Total assets	75,722,547	69,647,946
Total equity	20,694,398	18,217,394

For the nine months ended

For the nine months ended

	30 September 2022 (unaudited)	30 September 2021 (unaudited)
Operating income	8,586,687	7,446,641
Profit for the period	1,727,114	1,665,464
Net cash flows from / (used in) operating activities	1,849,123	(1,496,368)

The Company hereby reminds investors that the above unaudited operation summary for the first three quarters ended 30 September 2022 was prepared based on the Group's internal figures and management accounts which have not been reviewed or audited by the auditors of the Group. The Universal Leasing Consolidated Financial Information was prepared in accordance with the General Accepted Accounting Principles of the PRC, which may require adjustment during the course of auditing of the financial results of the Group, and the information contained therein is limited solely to the operation of Universal Leasing, which does not provide a full picture of the operation status of the Group or comparison with the Group.

Investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Genertec Universal Medical Group Company
Limited
 通用環球醫療集團有限公司
Peng Jiahong
Chairwoman of the Board

Beijing, PRC, 28 October 2022

As at the date of this announcement, the executive Directors are Ms. Peng Jiahong (Chairwoman), Mr. Wang Wenbing and Mr. Yu Gang; the non-executive Directors are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive Directors are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.